Citigroup’s Mersana Therapeutics MRSN Stock Holding History

Citigroup’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,600	Closed	-$164K	–	5674
2023 Q1	$164K	Hold	1,600	–	–	﹤0.01%	3828
2022 Q4	$234K	Buy	+1,600	New	+$270K	﹤0.01%	3638

Other funds holding MRSN

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Alamea Verwaltungs Edison, New Jersey $135M AUM 36.32% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citigroup's MRSN Position: Q4 2025 in Review

Citigroup sold out of Mersana Therapeutics (MRSN) in Q4 2025, closing a stake of 106 shares — an estimated $823 sold.

Citigroup first reported a position in MRSN in Q3 2017 and held it in 32 quarters. The position peaked at $3.72M in Q1 2021. 51 funds tracked by Wall St. Rank hold MRSN as of Q4 2025.

Citigroup reported no remaining Mersana Therapeutics position as of Q4 2025 after selling out during the quarter.
Citigroup sold 106 Mersana Therapeutics shares in Q4 2025, an estimated $823.
Citigroup first reported a position in Mersana Therapeutics in Q3 2017 and held it in 32 quarters.
Citigroup's Mersana Therapeutics position peaked at $3.72M in Q1 2021.
51 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.